Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Life Potentially Saved Through Hereditary Cancer Panel Testing.
Marks D, McHenry A, Biagi T, Stark E, Borum M, Lin P, Kaltman R. Marks D, et al. Among authors: kaltman r. J Oncol Pract. 2017 Apr;13(4):279-281. doi: 10.1200/JOP.2016.016170. Epub 2017 Feb 14. J Oncol Pract. 2017. PMID: 28195815 No abstract available.
A Feasibility Study of Group-Delivered Behavioral Interventions for Insomnia Among Breast Cancer Survivors: Comparing Cognitive Behavioral Therapy for Insomnia and a Mind-Body Intervention.
Arem H, Lewin D, Cifu G, Bires J, Goldberg E, Kaltman R, Power MC, Mauro LA, Kogan M. Arem H, et al. Among authors: kaltman r. J Altern Complement Med. 2019 Aug;25(8):840-844. doi: 10.1089/acm.2019.0038. Epub 2019 Jun 25. J Altern Complement Med. 2019. PMID: 31237434
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Casasanta N, Kipnis ST, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R. Casasanta N, et al. Among authors: kaltman r. Clin Breast Cancer. 2020 Apr;20(2):125-130. doi: 10.1016/j.clbc.2019.07.004. Epub 2019 Aug 21. Clin Breast Cancer. 2020. PMID: 31526714
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: kaltman r. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: kaltman r. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. medRxiv. 2023. PMID: 38105958 Free PMC article. Updated. Preprint.
14 results